Paolo Caravelli
University of Pisa
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Paolo Caravelli.
European Journal of Heart Failure | 2012
Frank Lloyd Dini; Ryan T. Demmer; Anca Simioniuc; Doralisa Morrone; Francesca Donati; Giacinta Guarini; Enrico Orsini; Paolo Caravelli; Mario Marzilli; P.C. Colombo
Chronic kidney disease (CKD) and right ventricular (RV) dysfunction are important predictors of prognosis in heart failure (HF). We investigated the relationship between RV dysfunction and CKD in outpatients with chronic systolic HF, an association which remains poorly defined.
American Journal of Cardiology | 2002
G. Mengozzi; Roberta Rossini; C Palagi; Giuseppe Musumeci; Anna Sonia Petronio; Ugo Limbruno; Paolo Caravelli; Vitantonio Di Bello; Mario Mariani
The aim of this study was to assess the role of intravenous myocardial contrast echocardiography (IMCE) in the prediction of left ventricular (LV) remodeling in patients with acute myocardial infarction (AMI). Sixty-three patients with AMI, who were successfully treated with acute coronary angioplasty, underwent IMCE and low-dose dobutamine echocardiography during hospital admission. IMCE was graded semiquantitatively on a score of 0 (no visible contrast effect), 0.5 (patchy myocardial contrast enhancement), and 1 (homogenous contrast effect). Patients were considered to have microvascular impairment if <50% of segments within the infarct-related area had score of 1. A mean perfusion score index was calculated for each patient. Patients with a good perfusion at IMCE (IMCE+) showed a lower creatine kinase peak (p = 0.001) and lower creatine kinase-MB (p = 0.01), and a better baseline regional contractile function compared with patients who had negative results at IMCE (IMCE-) (p <0.0001) and a higher amount of myocardial viability at low-dose dobutamine echocardiography (p = 0.03). At follow-up, a higher improvement in regional systolic function (p = 0.0006) was observed in IMCE+ patients, whereas IMCE- patients showed an evident increase in LV end-diastolic volume from baseline to 6-month follow-up (p <0.0001), implying LV remodeling, which has been associated with a higher incidence of adverse cardiac events (p = 0.005). By stepwise multiple regression analysis, microvascular impairment at IMCE was a significant independent predictor of LV remodeling (p <0.0001). Thus, IMCE seems to be an important diagnostic tool, able to predict LV remodeling in patients with AMI.
Annals of Noninvasive Electrocardiology | 2002
Paolo Caravelli; Marco De Carlo; Giuseppe Musumeci; Giuseppe Tartarini; Gherarducci G; Uberto Bortolotti; Massimo A. Mariani; And Mario Mariani
Background: AF is one of the most common complications after CABG. The aim of the study was to identify the risk factors for postoperative AF.
Congestive Heart Failure | 2012
Frank Lloyd Dini; Maya Guglin; Anca Simioniuc; Francesca Donati; Paolo Fontanive; Andrea Pieroni; Enrico Orsini; Paolo Caravelli; Mario Marzilli
In chronic heart failure (HF), high daily doses of furosemide have been associated with increased mortality. The authors sought to evaluate the relationships between orally administered furosemide doses, clinical status, left ventricular (LV) dysfunction, N-terminal proBNP (NT-proBNP), and outcome in 400 outpatients with chronic HF and LV ejection fraction (EF) ≤ 45%. Clinical status, NT-proBNP levels, and estimated glomerular filtration rate (eGFR) were evaluated. Median follow-up duration was 32 months. The median values of daily-dose furosemide and of furosemide dose normalized to body surface area were 25 mg (12.5-62.5 mg) and 15 mg/m(2) (13-34 mg/m(2)), respectively. A total of 32% of patients had decompensated HF according to Framingham score and criteria for congestion. In clinically stable patients, a multivariable Cox model, which included clinical and echocardiographic parameters plus NT-proBNP, hemoglobin, and eGFR, showed that normalized furosemide dose (P=.017), anemia (P=.060), age (P=.080), and New York Heart Association class (P=.080) were predictors of all cause-mortality. In patients with decompensated HF, LV end-systolic volume index (P=.018), NT-proBNP (P=.060), and reduced eGFR (P=.070) were independently related to the outcome. Normalized furosemide dose was a major determinant of prognosis in patients with chronic HF but without ongoing signs and symptoms, and this suggests a possible negative interaction of this drug in clinically stable patients.
European heart journal. Acute cardiovascular care | 2018
Enrico Orsini; Paolo Caravelli; Frank Lloyd Dini; Mario Marzilli
Background: Cardiac troponin is the most sensitive marker of myocardial injury, but controversy still exists about its role in detecting ischaemia. Methods: To investigate the role of troponin as a marker of stress-induced ischaemia, circulating high sensitivity cardiac troponin T (hs-cTnT) was measured and compared with the MB fraction of creatine kinase (CK-MB) in 125 patients undergoing a stress test (53 electrocardiogram/echo exercise, 42 echo dipyridamole and 30 echo dobutamine tests). Results: Plasma concentrations of hs-cTnT increased after the tests in 90/125 patients, while an increase of CK-MB was seen in 31/125 patients (p<0.0001). Overall, hs-cTnT significantly increased from 17.5±16.9 ng/l to 25.5±27.9 ng/l (p<0.0001), without significant changes of CK-MB. Significant increments in hs-cTnT were documented after exercise test (from 15.9±11.9 ng/l to 19.5±13.6 ng/l, p<0.0001) and dobutamine test (from 20.6±20.8 ng/l to 37.8±31.1 ng/l, p=0.0006), in absence of changes in CK-MB according to each stressor. Among the 125 tests, 84 were diagnosed as negative and 41 as positive for myocardial ischaemia. Significant increments in hs-cTnT were detected after both negative (from 18.6±19.2 ng/l to 27.1±32.1 ng/l, p=0.0018) and positive test (from 15.2±10.8 ng/l to 22.3±16.2 ng/l, p=0.0005), without significant changes of CK-MB according to the test result. Despite a positive correlation between stress-induced increase of hs-cTnT and obstructive coronary artery disease, the release of troponin was observed also in a significant proportion of patients without coronary stenoses. Left ventricular hypertrophy markedly enhanced myocardial release of troponin. Conclusions: Circulating troponin increases in most patients undergoing a stress test, irrespective of the test result and of coronary artery disease. Plasma release of troponin depends on multiple pathogenetic mechanisms, making the biomarker a not reliable tool in detecting transient ischaemia.
Il Nuovo Cimento D | 1989
Alberto Balbarini; L Becuzzi; Ombretta Biadi; Paolo Caravelli; Mario Mariani; Rita Mariotti; E. Bertolucci; A. Messineo; V. Rosso; Arnaldo Stefanini; U. Bottigli
SummaryThis paper presents a method for identification of coronary disease using the discriminant analysis. The set of discriminant variables used is composed by the general characteristics of the patient, the lipemic values, collected by a blood analysis, and some results of a cardiac catheterism. By using all the variables a total level of classification of about 89.9% is reached, separating the healthy patients from the sick patients affected by a coronary disease. The discriminant analysis is also performed using the general characteristics of the patient and the lipemic values only (i.e. noninvasive medical examinations), and general characteristics and some results of a cardiac catheterism only. In conclusion, the diagnosis of coronary artery disease, obtained by discriminant analysis of noninvasive data, seems to be good enough to discriminate sick from healthy people and to assign patients to a further protocol.
American Heart Journal | 2002
Anna Sonia Petronio; Giuseppe Musumeci; Ugo Limbruno; Marco De Carlo; Roberto Baglini; Giovanni Paterni; Maria Grazia Delle Donne; Paolo Caravelli; Carmela Nardi; Mario Mariani
American Journal of Hypertension | 2004
Vitantonio Di Bello; D Giorgi; Roberto Pedrinelli; E Talini; C Palagi; Maria Grazia Delle Donne; Giulio Zucchelli; Giulia Dell’Omo; Andrea Di Cori; Rita Dell’Anna; Paolo Caravelli; Mario Mariani
Journal of The American Society of Echocardiography | 2005
D Giorgi; Vitantonio Di Bello; E Talini; C Palagi; Maria Grazia Delle Donne; Carmela Nardi; Francesco Verunelli; Massimo A. Mariani; Andrea Di Cori; Paolo Caravelli; Mario Mariani
Journal of Cardiovascular Medicine | 2006
Maria Laura Canale; Andrea Camerini; Stefano Stroppa; Romana Prosperi Porta; Paolo Caravelli; Mario Mariani; Alberto Balbarini; Sergio Ricci